Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis

Nephron. 1996;74(1):72-8. doi: 10.1159/000189284.


We identified and quantified indoxyl-beta-D-glucuronide in uremic serum and urine to determine the metabolism of indoles including indoxyl sulfate in uremic patients. Serum levels of indoxyl-beta-D-glucuronide were markedly increased in undialyzed uremic patients, in patients on hemodialysis, and in patients on continuous ambulatory peritoneal dialysis. Urinary excretion of indoxyl-beta-D-glucuronide was also increased in undialyzed uremic patients. Urinary indoxyl-beta-D-glucuronide was significantly correlated with serum indoxyl sulfate, indicating that a high serum level of indoxyl sulfate leads to the enhanced synthesis of indoxyl-beta-D-glucuronide. Oral sorbent (AST-120) administration markedly decreased the serum and urine levels of indoxyl-beta-D-glucuronide as well as indoxyl sulfate in the undialyzed uremic patients. Serum indoxyl-beta-D-glucuronide could be efficiently removed by hemodialysis despite its high protein-binding ratio of about 50%. In conclusion, the serum level of indoxyl-beta-D-glucuronide increases in uremic patients due to renal insufficiency and its increased production. The production of indoxyl-beta-D-glucuronide can be suppressed by oral sorbent treatment, and serum indoxyl-beta-D-glucuronide can be efficiently removed by hemodialysis.

Publication types

  • Clinical Trial

MeSH terms

  • Adsorption
  • Carbon / pharmacology*
  • Chromatography, High Pressure Liquid
  • Female
  • Glucuronates / blood*
  • Glucuronates / urine
  • Humans
  • Indoles / blood*
  • Indoles / urine
  • Luminescent Measurements
  • Male
  • Mass Spectrometry
  • Oxides / pharmacology*
  • Peritoneal Dialysis, Continuous Ambulatory
  • Protein Binding
  • Renal Dialysis*
  • Uremia / blood*
  • Uremia / drug therapy*


  • Glucuronates
  • Indoles
  • Oxides
  • indoxyl glucuronide
  • Carbon
  • AST 120